Sanara MedTech Reports 28% Increase in <a href="https://laohu8.com/S/QTWO">Q2</a> Net Revenue to $25.8 Million; Achieves $0.5 Million Net Income
Sanara MedTech Inc., a medical technology company focused on surgical, chronic wound, and skin markets, reported a 28% increase in net revenue for the second quarter of 2025, reaching $25.8 million, compared to $20.2 million in the same quarter of 2024. The Sanara Surgical segment achieved a net income of $0.5 million and a Segment Adjusted EBITDA of $4.7 million in the second quarter, reflecting significant improvements year-over-year. For the first half of 2025, the segment incurred a net loss of $0.1 million but generated $7.4 million in Segment Adjusted EBITDA. In the THP segment, Sanara launched a pilot program with a wound care provider group in late June 2025, marking the beginning of patient encounters under this initiative. The segment, however, recorded a Segment Adjusted EBITDA of $(4.1) million for the first six months of 2025, compared to $(1.6) million for the same period in 2024. The company also announced a process to evaluate strategic alternatives for its Tissue Health Plus, LLC subsidiary. Cash flow from operating activities improved, with $0.7 million generated in the first half of 2025, compared to $3.0 million used in operating activities during the same period in 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanara Medtech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-011878), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.